Business
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron"), a leading global biotechnology company. This amendment not only signifies a major upgrade in long-term partnership between the two companies, but also marks the beginning of a new phase of collabora
About this update from Jw (cayman) Therapeutics Co. Ltd.
[{"type":"text","content":"SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron"), a leading global biotechnology company. This amendment not only signifies a major upgrade in long-term partnership between the two companies, but also marks the beginning of a new phase of collaboration in TCR-T cell therapy and platform innovation.","length":601,"tagName":"p"},{"type":"text","content":"The aggregate consideration receivable by the Company under the Amendment, consisting of the MAGE-A4 Product Development Milestone Payments, the DPP Regulatory Milestone Payments, the Option Exercise Fee, the LVMP Milestone Payments. Aggregate consideration under the amendment will not exceed approximately US$50 million.","length":322,"tagName":"p"},{"type":"text","content":"Under the amended agreement, Regeneron will fund certain development activities performed by JW Therapeutics relating to the MAGE-A4 Product. Regeneron will pay the Company an upfront payment upon execution of the Amendment and a series of one-time, non-refundable milestone payments upon achievement of certain development milestone events as set forth in the Amendment. This cost-sharing mechanism enhances JW Therapeutics' financial position by reducing capital expenditure while ensuring continued progress on a solid tumor program addressing a huge unmet medical need. JW Therapeutics will retain the right to develop and commercialize this product in the Greater China region.","length":686,"tagName":"p"},{"type":"text","content":"The Amendment further broadens the collaboration scope to incorporate core technology licensing. Regeneron has been granted non-exclusive global license under JW Therapeutics' proprietary Drug Product Process, along with an option to license JW Therapeutics' Lentiviral Vector Manufacturing Process. The above self-developed internal process platform has been validated by a leading global partner, underscoring JW Therapeutics' process innovation, GMP maturity, and technical excellence.","length":500,"tagName":"p"},{"type":"text","content":"Under these non-exclusive licensing t...